论文部分内容阅读
目的探讨进展性胃癌术中行区域性缓释化疗的安全性评价。方法 48例病例为我院外科采用手术治疗的胃癌患者,随机分成两组各24例,一组患者采用5-FU区域性缓释化疗治疗(区域组),一组采用传统的全身范围化疗(全身组)。结果区域组患者的5年无瘤生存率和生存率均明显高于全身组患者(P<0.05);区域组患者的生活质量评分和化疗毒副作用的评分明显优于全身组患者(P<0.05)。结论对进展性胃癌术中行区域性缓释化疗是安全的、有效的,值得临床推广。
Objective To evaluate the safety of regional delayed-release chemotherapy in patients with advanced gastric cancer. Methods Forty-eight cases of gastric cancer treated surgically in our hospital were randomly divided into two groups of 24 patients. One group was treated with 5-FU regional controlled release chemotherapy (regional group), and the other group was treated with traditional systemic chemotherapy Whole body group). Results The 5-year disease-free survival rate and survival rate in the regional group were significantly higher than those in the systemic group (P <0.05). The quality of life scores and the chemotherapy side effects in the regional group were significantly better than those in the systemic group (P <0.05) ). Conclusions Regional slow-release chemotherapy for advanced gastric cancer is safe, effective and worthy of clinical promotion.